Nurse Practitioner Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Erin Krstanovic

Gastroenterology Frederick, MD Nurse Practitioner

NPI 1588317572 CMS profile 11327186

85 Thomas Johnson Ct Ste B, Frederick, MD 21702

Open in the dashboard

General payments

$5,933

294 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Erin Krstanovic of Frederick, MD is reported in the CMS Open Payments database as having received $5,933 across 294 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 70th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,951 77
2024 General $1,857 81
2023 General $1,759 110
2022 General $366 26

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Erin Krstanovic
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Erin Krstanovic were reported at $1,951. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Erin Krstanovic Gastroenterology median Middle half National median
2019 $0 $417 $126–$1,100 $163
2020 $0 $224 $74–$624 $114
2021 $0 $352 $106–$1,054 $132
2022 $366 $448 $129–$1,270 $149
2023 $1,759 $533 $150–$1,390 $160
2024 $1,857 $605 $160–$1,606 $164
2025 $1,951 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. AbbVie, Inc. $1,183 37 payments
  2. Salix Pharmaceuticals, a division of Bausch Health US, LLC $742 63 payments
  3. Genzyme Corporation $550 24 payments
  4. Regeneron Healthcare Solutions, Inc. $444 23 payments
  5. Lilly USA, LLC $402 11 payments
  6. Pfizer Inc. $316 16 payments
  7. Madrigal Pharmaceuticals $254 10 payments
  8. Intercept Pharmaceuticals, Inc. $253 16 payments
  9. Celgene Corporation $239 22 payments
  10. Janssen Biotech, Inc. $200 7 payments
  11. Other $1,350 65 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $5,826 286 payments
  2. Education $107 8 payments
Products named General payments · program years 2022–2025
  1. XIFAXAN $757 64 payments
  2. DUPIXENT Immunology $530 23 payments
  3. OMVOH $402 11 payments
  4. SKYRIZI Immunology $387 10 payments
  5. RINVOQ $371 14 payments
  6. SKYRIZI Immunology $349 8 payments
  7. ZEPOSIA $348 22 payments
  8. VELSIPITY $285 14 payments
  9. DUPIXENT Inflammation And Immunology $268 14 payments
  10. TRULANCE $260 18 payments
  11. Other $2,845 151 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 16 drugs

Part D claims

823

Median for Nurse Practitioner: 389

Drug cost

$148,522

Median for Nurse Practitioner: $21,885

Branded share of claims

32%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Creon Lipase/Protease/Amylase Brand 11 $65,975
Linzess Linaclotide Brand 27 $37,011
Viberzi Eluxadoline Brand 12 $18,238
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 117 $7,526
Omeprazole Generic 215 $3,654
Pantoprazole Sodium Generic 168 $3,306
Rabeprazole Sodium Generic 41 $2,567
Esomeprazole Magnesium Generic 15 $2,465
Sutab Sod Sulf/Pot Chloride/Mag Sulf Brand 14 $2,214
Colestipol Hcl Generic 19 $1,934

The 10 drugs with the highest cost, of 16 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 7 billing codes

Paid by Medicare

$43,106

Medicare's payments for the services billed

Medicare patients

378

Average age 72

Services billed

526

224 women, 154 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 69%
Arthritis 52%
Diabetes 31%
Ischemic heart disease 29%
Depression 25%
Osteoporosis 19%
Chronic kidney disease 18%
Cancer 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 23 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SKYRIZI
  • AbbVie, Inc. $303
$303 — —
DUPIXENT
  • GENZYME CORPORATION $126
  • Regeneron Healthcare Solutions, Inc. $109
$235 — —
OMVOH
  • Lilly USA, LLC $230
$230 — —
LINZESS
  • Ironwood Pharmaceuticals, Inc $56
  • AbbVie, Inc. $42
$99 27 —
VELSIPITY
  • PFIZER INC. $92
$92 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 23 in the dashboard with a free account

Records

294 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record